30 results about "Animal cell line" patented technology

The invention discloses a human normal kidney immortalized cell line NRC-X1 and application thereof, and belongs to the field of microbial animal cell lines. The human normal kidney immortalized cell line is named as NRC-X1, and the preservation number is CCTCC (China Center For Type Culture Collection) NO: C2025168. The invention also discloses the application of the human normal kidney immortalized cell line NRC-X1 in a virus infection mechanism. The invention also discloses application of the human normal kidney immortalized cell line NRC-X1 in research of drug renal toxicity evaluation. The invention also discloses the application of the human normal kidney immortalized cell line NRC-X1 in bioartificial kidney and cell therapy. The invention also discloses application of the human normal kidney immortalized cell line NRC-X1 in research of kidney physiological and pathological mechanisms.

The invention discloses an immortalized human pelvic kidney cancer related fibroblast line RPCcaf-X1 and application thereof, and belongs to the field of microbial animal cell lines. The immortalized human pelvic kidney cancer related fibroblast line is named as RPCcaf-X1, and the preservation number of the immortalized human pelvic kidney cancer related fibroblast line is CCTCC (China Center For Type Culture Collection) NO: C2025306. The invention also discloses the application of the immortalized human pelvis and kidney cancer related fibroblast line RPCcaf-X1 in the research of the pathogenic mechanism of the pelvis and kidney cancer. The invention further discloses the application of the immortalized human pelvic kidney cancer related fibroblast line RPCcaf-X1 in tumor microenvironment research. The invention further discloses the application of the immortalized human pelvic kidney cancer related fibroblast line RPCcaf-X1 in drug screening or research and development. The invention further discloses the application of the immortalized human pelvis and kidney cancer related fibroblast line RPCcaf-X1 in screening of potential biomarkers related to pelvis and kidney cancer.

The invention discloses a human immortalized pure renal cyst cell line SRC-X1 and application thereof, and belongs to the field of microbial animal cell lines. The human immortalized pure renal cyst cell line is named as SRC-X1, the cell line is preserved in the China Center for Type Culture Collection on September 19, 2025, and the preservation number is CCTCC NO: C2025303. The human immortalized pure renal cyst cell line SRC-X1 is applied to preparation, screening or evaluation of renal cyst treatment drugs. The invention also discloses the application of the human immortalized pure renal cyst cell line SRC-X1 as a renal cyst cell model. The human immortalized pure renal cyst cell line SRC-X1 is applied to renal cyst basic or clinical research as an experimental material.

The invention discloses a human extrahepatic bile duct cancer cell line EBC-X1 and application thereof, and belongs to the field of microbial animal cell lines. The human extrahepatic bile duct cancer cell line is named as a human extrahepatic bile duct cancer cell line EBC-X1, and the preservation number of the human extrahepatic bile duct cancer cell line EBC-X1 is CCTCC No: C2024318. The human extrahepatic bile duct cancer cell line EBC-X1 can be applied to establishment of a cell model for occurrence, development or metastasis of extrahepatic bile duct cancer. The human extrahepatic bile duct cancer cell line EBC-X1 can be applied to research on differentiation mechanism, cell morphology and dysfunction and tumor infiltration and metastasis mechanism of extrahepatic bile duct cancer and cell models for guiding clinical comprehensive diagnosis and treatment. The human extrahepatic cholangiocarcinoma cell line EBC-X1 can be applied to research on the occurrence mechanism of extrahepatic cholangiocarcinoma and screening of drugs for preventing and treating extrahepatic cholangiocarcinoma. The extrahepatic bile duct cancer cell line EBC-X1 can be applied to establishment of an extrahepatic bile duct cancer animal model.

The invention discloses a human-derived ampulla cancer cell line DPC-X5 and application thereof, and belongs to the field of microbial animal cell lines. The human-derived ampulla cancer cell line is named as a human-derived ampulla cancer cell line (homo sapiens) DPC-X5, and is preserved in the China Center for Type Culture Collection on October 30, 2025, and the preservation number is CCTCC NO: C202580. The human-derived ampulla cancer cell line DPC-X5 can be applied to establishment of a cell model for occurrence, development or metastasis of ampulla cancer. The human-derived ampulla cancer cell line DPC-X5 can be applied to cell models for researching differentiation mechanisms, cell morphology and dysfunction and tumor infiltration and metastasis mechanisms of ampulla cancer and guiding clinical comprehensive diagnosis and treatment. The human-derived ampulla cancer cell line DPC-X5 can be applied to research on the occurrence mechanism of the ampulla cancer and screening of drugs for preventing and treating the ampulla cancer. The human-derived ampulla cancer cell line DPC-X5 can be applied to establishment of an ampulla cancer animal model.

The application belongs to the field of microbial animal cell lines, and relates to a human immortalized simple renal cyst cell line SRC-X1 and an application thereof. The human immortalized simple renal cyst cell line is named SRC-X1, the cell line has been preserved in the China Center for Type Culture Collection on September 19, 2025, and the preservation number is CCTCC NO: C2025303. The application of the human immortalized simple renal cyst cell line SRC-X1 in preparation, screening or evaluation of renal cyst treatment drugs. The application of the human immortalized simple renal cyst cell line SRC-X1 as a renal cyst cell model. The application of the human immortalized simple renal cyst cell line SRC-X1 as experimental material in renal cyst basic or clinical research.

The present invention relates to a mammalian non-human cell line, specifically a Chinese hamster ovary (CHO) cell line, in which the genes are modified to express CP77, K1L and / or SPI-1, which are host range genes of poxviruses not expressed by MVA, and to the use of such cell lines in the replication of MVA.

Disclosed are genetically controlled circuits, cells and methods that use repressor polypeptides to reduce the rate of transcription of an exogenous therapeutic polypeptide encoding gene in response to changing conditions. [Selection diagram] None

The invention discloses a human-derived ampulla cancer cell line DPC-X2 and application thereof, and belongs to the field of microbial animal cell lines. The human-derived ampulla carcinoma cell line is named as the human-derived ampulla carcinoma cell line (homo sapiens) DPC-X2, and is preserved in the China Center for Type Culture Collection on October 30, 2025, and the preservation number is CCTCC NO: C202579. The human-derived ampulla cancer cell line DPC-X2 can be applied to establishment of a cell model for occurrence, development or metastasis of ampulla cancer. The human-derived ampulla cancer cell line DPC-X2 can be applied to cell models for researching differentiation mechanisms, cell morphology and dysfunction and tumor infiltration and metastasis mechanisms of ampulla cancer and guiding clinical comprehensive diagnosis and treatment. The human-derived ampulla cancer cell line DPC-X2 can be applied to research on the occurrence mechanism of the ampulla cancer and screening of drugs for preventing and treating the ampulla cancer. The human-derived ampulla cancer cell line DPC-X2 can be applied to establishment of an ampulla cancer animal model.

The human primary undifferentiated pleomorphic sarcoma cell line HUPS‑X1 and its application belong to the field of microbial animal cell lines. The human primary undifferentiated pleomorphic sarcoma cell line is named human primary undifferentiated pleomorphic sarcoma cell line HUPS‑X1, and the deposit number is CCTCC NO: C2024319. The human primary undifferentiated pleomorphic sarcoma cell line HUPS‑X1 can be used in establishing a cell model for the occurrence, development or metastasis of primary undifferentiated pleomorphic sarcoma of the liver; it can be used in studying the differentiation mechanism, cell morphology and functional abnormalities, tumor infiltration and metastasis mechanism of primary undifferentiated pleomorphic sarcoma of the liver, and in guiding the cell model for comprehensive clinical diagnosis and treatment; it can be used in studying the occurrence mechanism of primary undifferentiated pleomorphic sarcoma of the liver; it can be used in establishing an animal model of primary undifferentiated pleomorphic sarcoma of the liver.

Novel gene repressor systems are provided that are useful in animal cells that include engineered repressors with altered ligand-binding domains (LBDs) and DNA-binding domains (DBDs), as well as mutated operator sequences. In one aspect, the systems enable independent, drug-inducible control of multiple genes within a single animal or animal cell line. In one aspect, the disclosure provides both tetracycline-responsive repressors and sulfonylurea (SU)-responsive repressors — e.g., variants that respond specifically to ethametsulfuron-methyl (Es) or chlorsulfuron (Cs). Mutations are introduced to either the LBD (to alter ligand specificity), DBD (to alter operator binding), or the operator sequence itself, resulting in orthogonal systems.

Human extrahepatic bile duct cancer cell line EBC-X1 and its applications belong to the field of microbial animal cell lines. The human extrahepatic bile duct cancer cell line is named human extrahepatic bile duct cancer cell line EBC-X1, and the preservation number is CCTCC No: C2024318. The human extrahepatic bile duct cancer cell line EBC-X1 can be used in the establishment of cell models for the occurrence, development or metastasis of extrahepatic bile duct cancer. The human extrahepatic bile duct cancer cell line EBC-X1 can be used in cell models for studying the differentiation mechanism, abnormal cell morphology and function, tumor invasion and metastasis mechanism of extrahepatic bile duct cancer and guiding clinical comprehensive diagnosis and treatment. The human extrahepatic bile duct cancer cell line EBC-X1 can be used in studying the pathogenesis of extrahepatic bile duct cancer and screening drugs for the prevention and treatment of extrahepatic bile duct cancer. The extrahepatic bile duct cancer cell line EBC-X1 can be used in the establishment of animal models of extrahepatic bile duct cancer.

The present invention is related to a DNA array-based method of assessing the effect of at least one test component of cell medium on at least one phenotype of interest of a test mammalian cell line cultured in cell media comprising the test component, the method comprising the steps of:(a) determining a test methylation profile of one or more pre-selected methylation sites within the DNA of the test cell line;(b) comparing the test methylation profile obtained from (a) with at least one control methylation profile from the same strain of mammalian cell line cultured in cell media without the test component; andwherein a significant similarity in the test methylation profile of (a) compared to the control methylation profile, is indicative of the test cell having the phenotype of interest and the test component not having an effect on the phenotype of interest; andwherein a significant difference in the test methylation profile of (a) compared to the control methylation profile, is indicative of the test cell having the phenotype of interest and the test component having an effect on the phenotype of interest and wherein the method comprises a further step of:(c) comparing the test methylation profile obtained from (a) with(i) at least one first reference methylation profile obtained from a first mammalian reference cell line that displays at least one phenotype of interest; and / or(ii) at least one second reference methylation profile obtained from a second mammalian reference cell line that does not display the phenotype of interest; andwherein the reference cell lines are not in contact with the test component; andwherein a significant similarity in the test methylation profile of (a) compared to the first or second reference methylation profile, is indicative of the test cell having the phenotype of interest or not having the phenotype of interest respectively; andwherein a difference in the test methylation profile of (a) compared to the first or second reference methylation profile, is indicative of the test cell not having the phenotype of interest or having the phenotype of interest.

The human liver metastasis-derived colon cancer cell line CRC-X1 and its application belong to the field of microbial animal cell lines. The human colon cancer cell line is named Homo sapiens CRC-X1, and was preserved in the China Center for Type Culture Collection on November 22, 2025, with the preservation number CCTCC NO: C2025354. The human liver metastasis-derived colon cancer cell line CRC-X1 can be applied in the establishment of a cell model of colon cancer occurrence, development or metastasis; CRC-X1 can be applied in the cell model of studying the differentiation mechanism of colon cancer, cell morphology and functional abnormalities, tumor infiltration and metastasis mechanism, and guiding clinical comprehensive diagnosis and treatment. CRC-X1 can be applied in the study of the mechanism of colon cancer and the screening of drugs for preventing and treating colon cancer. CRC-X1 can be applied in the establishment of an animal model of colon cancer.

This invention relates to synthetic biology, gene and cell therapy, and particularly to a gene translation system regulated by non-natural amino acids and its applications. This gene translation system precisely regulates gene expression initiation using non-natural amino acids. The invention also provides eukaryotic expression vectors, mammalian cell lines, microcapsules, vacuum fiber tubes, and non-natural amino acid cookies containing the aforementioned gene translation system. Furthermore, this invention discloses that the multifunctional platform can precisely regulate insulin expression and release for diabetes treatment; this gene expression regulation platform can be used to construct complex biological computer-controlled systems. This invention provides a powerful new gene expression regulation tool for gene therapy and cell therapy.

The invention discloses a method for recovering adipogenic gene expression and adipogenic capacity of bovine immortalized adipocytes based on siRNA (small interfering Ribonucleic Acid). In order to solve the problems that bovine immortalized adipocytes established by overexpression of SV40 T-antigen genes are inhibited in adipogenesis related gene expression and abnormal in adipogenesis ability, the invention inhibits the expression of SV40 virus T-antigen in bovine adipocytes by designing, screening and identifying specific efficient interfering siRNA (small interfering ribonucleic acid) aiming at the SV40 virus T-antigen. Therefore, the inhibition effect of SV40 on adipogenic gene expression is relieved, the expression level and the adipogenic capacity of the adipogenic gene in the bovine immortalized adipocytes are recovered, and the method plays a key role in breaking through the bottleneck problem of developing species-specific adipodifferentiation mechanism research by utilizing the bovine immortalized adipocytes and getting rid of the current situation of developing research by depending on a mode animal cell line for a long time.

The present invention relates to a DNA array-based method that evaluates the effect of at least one test component of a cell culture medium on at least one phenotype of interest of a test mammalian cell line cultured in a cell culture medium comprising the test component, the method comprises the steps of: (a) determining a test methylation profile of one or more preselected methylation sites within DNA of a test cell line; (b) comparing the test methylation profile from (a) to at least one control methylation profile from the same line of mammalian cell lines cultured in a cell culture medium free of the test component; and wherein a significant similarity of the test methylation profile of (a) compared to the control methylation profile indicates that the test cell has a phenotype of interest and the test component does not act on the phenotype of interest; and wherein a significant difference in the test methylation profile of (a) compared to the control methylation profile indicates that the test cell has a phenotype of interest and the test component has an effect on the phenotype of interest, and wherein the method comprises the further steps of: (c) comparing the test methylation profile from (a) to (i) at least one first reference methylation profile from a first mammalian reference cell line exhibiting at least one phenotype of interest; and / or (ii) at least one second reference methylation profile obtained from a second mammalian reference cell line that does not exhibit a phenotype of interest; and wherein the reference cell line is not in contact with the test component; and wherein a significant similarity of the test methylation profile of (a) compared to the first reference methylation profile or the second reference methylation profile is indicative of the test cell having or not having a phenotype of interest, respectively; and wherein a difference in the test methylation profile of (a) compared to the first reference methylation profile or the second reference methylation profile indicates that the test cell has no phenotype of interest or has a phenotype of interest.

The application discloses a method for continuous editing of multi-site chromosomes in eukaryotic cells. The application provides a method for integrating the genome of eukaryotic cells, comprising: using a knock-in site-specific recombination site (such as noxM) in the genome of eukaryotic cells, realizing integration of a large fragment circular DNA molecule at a specific site of the genome under the action of a knock-in site-specific recombinase (such as Nigri), and simultaneously using an adjacent knock-out site-specific recombination site (such as loxP or a mutant thereof), rearranging the related sites under the action of a knock-out site-specific recombinase (such as Cre), so as to realize continuity of integration. The novel editing platform of high-efficiency site-specific recombination provided by the application can realize directional, continuous and multi-site integration of a large fragment DNA in eukaryotic cells, and the application has important application prospects in the field of biological technologies including plant breeding, animal cell line development, fungus engineering and the like.

The invention belongs to the technical field of microbial animal cell lines, and particularly relates to a mouse intrahepatic bile duct cancer cell line mICC-K and application thereof. The mouse intrahepatic bile duct cancer cell line mICC-K is preserved in the China Center for Type Culture Collection on January 23, 2025, and the preservation number of the mouse intrahepatic bile duct cancer cell line mICC-K is CCTCC NO: C202538. The mouse intrahepatic cholangiocarcinoma spontaneous tumor is induced through AKT, YAP and SB plasmid systems by utilizing a high-pressure hydrodynamic method caudal vein plasmid injection method, so that the mouse intrahepatic cholangiocarcinoma cell line is obtained, and meanwhile, a KRASG12D mutation site is introduced, so that the blank of lack of a stable mouse in-vivo and in-vitro model in the current domestic intrahepatic cholangiocarcinoma research is filled, and the mouse intrahepatic cholangiocarcinoma cell line is developed. In addition, a stable model is provided for drug target research aiming at KRAS mutation.

Novel gene repressor systems are provided that are useful in animal cells that include engineered repressors with altered ligand-binding domains (LBDs) and DNA-binding domains (DBDs), as well as mutated operator sequences. In one aspect, the systems enable independent, drug-inducible control of multiple genes within a single animal or animal cell line. In one aspect, the disclosure provides both tetracycline-responsive repressors and sulfonylurea (SU)-responsive repressors — e.g., variants that respond specifically to ethametsulfuron-methyl (Es) or chlorsulfuron (Cs). Mutations are introduced to either the LBD (to alter ligand specificity), DBD (to alter operator binding), or the operator sequence itself, resulting in orthogonal systems.

The application discloses a human ampullary carcinoma cell line DPC-X5 and an application thereof, and belongs to the field of microbial animal cell lines. The human ampullary carcinoma cell line is named as a human ampullary carcinoma cell line (homo sapiens) DPC-X5, has been preserved in the China Center for Type Culture Collection on October 30, 2025, and the preservation number is CCTCC NO: C202580. The human ampullary carcinoma cell line DPC-X5 can be applied to the establishment of a cell model of ampullary carcinoma occurrence, development or metastasis. The human ampullary carcinoma cell line DPC-X5 can be applied to the research of a cell model of differentiation mechanism, cell morphology and functional abnormality, tumor infiltration and metastasis mechanism of ampullary carcinoma and guidance of clinical comprehensive diagnosis and treatment. The human ampullary carcinoma cell line DPC-X5 can be applied to the research of an occurrence mechanism of ampullary carcinoma and screening of drugs for preventing and treating ampullary carcinoma. The human ampullary carcinoma cell line DPC-X5 can be applied to the establishment of an animal model of ampullary carcinoma.

The present invention relates to a method comprising the steps of a) contacting ex vivo a cell from a mammalian cell line capable of secreting cytokines in a liquid medium with a set of antibodies from a blood sample from a mammalian subject which is known to be healthy or to suffer from a first disease; b) detecting the level of at least one cytokine present in the liquid medium following step a); c) contacting ex vivo a cell from the mammalian cell line capable of secreting cytokines with a set of antibodies from a blood sample from a mammalian reference subject which is known to be healthy or to suffer from a second disease in a liquid medium; d) detecting the level of the at least one cytokine present in the liquid medium following step c); e) determining a cytokine signature by determining the difference between the level of the at least one cytokine determined in step b) and the level of the at least one cytokine determined in step d), wherein the method is a method for aiding in detecting or diagnosing a disease, a method for aiding in distinguishing between a first disease and a second disease, or a method for aiding in diagnosing whether a mammalian subject is likely to suffer from a disease.

The application belongs to the field of microorganism animal cell lines, and relates to a human normal kidney immortalized cell line NRC-X1 and application thereof. The human normal kidney immortalized cell line is named NRC-X1, and the preservation number is CCTCC NO: C2025168. The application of the human normal kidney immortalized cell line NRC-X1 in a virus infection mechanism. The application of the human normal kidney immortalized cell line NRC-X1 in research on drug nephrotoxicity evaluation. The application of the human normal kidney immortalized cell line NRC-X1 in a biological artificial kidney and cell therapy. The application of the human normal kidney immortalized cell line NRC-X1 in research on kidney physiological and pathological mechanisms.

The present application relates to a protein for regulating the activity of a mitochondrial calcium channel and its application in preventing and treating obesity and related diseases, and belongs to the field of adipose tissue and related metabolism. The technical problem to be solved by the present application is how to prevent and / or treat obesity or obesity-related diseases. To solve the above technical problem, the present application provides a protein, which is an EMRE-UCP1 protein, wherein the EMRE-UCP1 protein is a protein fused from a mitochondrial calcium ion transport regulatory protein and a uncoupling protein-1. To solve the above technical problem, the present application provides a method for drug screening, wherein the method comprises using the transgenic animal cell line, or the transgenic animal tissue, or the transgenic animal organ of B11) to perform drug screening, and the drug is a drug for preventing and / or treating obesity or obesity-related diseases.

The invention discloses a salt-tolerant bacillus strain with broad-spectrum antibacterial activity on gram-positive drug-resistant bacteria and application thereof, and belongs to the field of microbial animal cell lines, the salt-tolerant bacillus strain is separated from intestinal tracts of patients in the recovery period of chronic diarrhea, is named as SH1, has an obvious bacteriostatic effect on clinically common gram-positive drug-resistant pathogenic bacteria, and can be used for preparing drugs for treating chronic diarrhea. A certain bacteriostatic effect is achieved on gram-negative drug-resistant bacteria. The size of a genome of the salt-tolerant bacillus strain SH1 is 4152283 bp, the salt-tolerant bacillus strain SH1 comprises 12 plasmids, the salt-tolerant bacillus strain SH1 is preserved in China General Microbiological Culture Collection Center (CGMCC) on November 23, 2023, and the preservation number of the salt-tolerant bacillus strain SH1 is CGMCC No. 29118. The invention also relates to an application of the salt-tolerant bacillus SH1 in a medicine for resisting gram-positive drug-resistant bacteria. According to the present invention, the bacterial strain having broad-spectrum antibacterial activity on the clinical common drug-resistant pathogenic bacteria is separated from the intestinal flora of the patient in the recovery phase of the chronic diarrhea, such that the foundation is laid for the exploration of the novel antibacterial molecules having characteristics of low toxicity, no harm, drug resistance generation resistance, and strong pertinence, wherein the novel antibacterial molecules have characteristics of low toxicity, no harm, and strong pertinence.

Development of media and feeds for CHO cells The present invention provides a DNA array-based method for assessing the effect of at least one test component of a cell culture medium on at least one phenotype of interest in a test mammalian cell line cultured in the cell culture medium comprising the test component, comprising: (a) measuring a test methylation profile of one or more preselected methylation sites within the DNA of a test cell line; (b) comparing the test methylation profile obtained from (a) with at least one control methylation profile obtained from the same mammalian cell line cultured in a cell culture medium that does not contain the test component. and a significant similarity between the test methylation profile and the control methylation profile in (a) indicates that the test cell has the phenotype of interest and that the test component does not affect the phenotype of interest; a significant difference between the test methylation profile of (a) and the control methylation profile indicates that the test cell has a phenotype of interest and that the test component affects the phenotype of interest; (c) The test methylation profile obtained from (a) (i) at least one first control methylation profile obtained from a first mammalian control cell line exhibiting at least one phenotype of interest; and / or (ii) at least one second control methylation profile obtained from a second mammalian control cell line that does not exhibit the phenotype of interest; Process to compare with and The control cell line was not in contact with the test component. a significant similarity between the test methylation profile of (a) and the first or second control methylation profile indicates that the test cell has a phenotype of interest or does not have a phenotype of interest, respectively; wherein a difference between the test methylation profile of (a) and the first or second control methylation profile indicates that the test cell does not have a phenotype of interest or that the test cell has a phenotype of interest.

The invention discloses a human pancreatic cancer cell line PDAC-X6 and application thereof, and belongs to the field of microbial animal cell lines. The human pancreatic cancer cell line is named as a human pancreatic cancer cell line PDAC-X6 homo sapiens, and is preserved in the China Center for Type Culture Collection on November 22, 2025, and the preservation number is CCTCC NO: C2025355. The human pancreatic cancer cell line PDAC-X6 can be applied to establishment of a cell model for occurrence, development or metastasis of pancreatic cancer. The human pancreatic cancer cell line PDAC-X6 can be applied to cell models for studying the differentiation mechanism, cell morphology and dysfunction and tumor infiltration and metastasis mechanism of pancreatic cancer and guiding clinical comprehensive diagnosis and treatment. The human pancreatic cancer cell line PDAC-X6 can be applied to research on the occurrence mechanism of pancreatic cancer and screening of drugs for preventing and treating pancreatic cancer. The human pancreatic cancer cell line PDAC-X6 can be applied to establishment of a pancreatic cancer animal model.

The present invention relates to the identification of cell models that support bocavirus infection and its application. The present invention selected 29 human cell lines derived from kidney, lung, brain, lymphocytes, intestine, muscle, thyroid and mammary gland, and 7 animal cell lines derived from mice, monkeys, dogs, pigs and cattle for evaluation, and found that compared with Caco-2 cells, only HT-29 and MA104 cells had higher levels of intracellular viral RNA transcription; further detection of intracellular viral DNA levels through infection system found that compared with Caco-2 cells, only MA104 supported higher levels of viral replication. Finally, through experimental tests such as virus binding and internalization, virus replication level, virus particle morphology and virus particle reinfection, it was confirmed that human bocavirus type I has a complete life cycle in MA104 cells, including virus entry, replication, assembly and release.

The present invention relates to a DNA methylation-based array comprising at least: a first plurality of different positions, each position having at least one probe molecule comprising a nucleic acid sequence complementary to a CpG site of a first plurality of CpG sites from a first animal species; and a second plurality of different positions, each position having at least one probe molecule comprising a nucleic acid sequence complementary to a CpG site from a second plurality of CpG sites of a second animal species wherein the first and second animal species are each independently selected from the group consisting of viruses, mammals, birds, and aquatic animals, and the mammal is at least one livestock or animal cell line; -said birds are at least one poultry; and-said aquatic animal is at least one crustacean, cephalopoda or fish, and wherein said first plurality of CpG sites comprises at least 1000 CpG sites of said first animal species; and the second plurality of CpG sites comprises at least 1000 CpG sites of the second animal species.

The invention discloses application of an MIDN gene in prevention and treatment of porcine reproductive and respiratory syndrome virus, and belongs to the technical field of veterinary biological products. The research finds that the MIDN gene participates in the PRRSV infection process for the first time, PRRSV infection can be remarkably inhibited through overexpression of the MIDN gene, and the MIDN gene can be used for preventing and treating the PRRSV; by knocking out the MIDN gene in an animal cell line, PRRSV infection of the cell line can be promoted. The porcine reproductive and respiratory syndrome virus super-susceptible cell line provided by the invention has super-strong infection ability to different types of PRRSV, and can increase the virus infection titer and shorten the infection time; the method can be used for rapid high-titer preparation of PRRSV, and provides a susceptible cell line for efficient production of PRRSV vaccines.